Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Research and Innovation Action · Running

UNDINE The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine

Coordinator
Aarhus Universitet, Denmark
Runs
1 June 2022 to 31 May 2026
Status
Running
EU funding
€6.7m
Total cost
€6.7m
Partners
22 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101057100

What the project is doing

In the project's own words, from its summary on CORDIS.

The consequences of SARS-CoV-2 exposure range from a lack of infection to lethal COVID-19. This immense inter-individual clinical variability is the key scientific and medical enigma in the field. While age and certain co-morbidities are known to influence disease outcome, these parameters do not explain all variation. In addition, there are other SARS-CoV-2 phenotypes of clinical importance: multisystem inflammatory syndrome in children and adults (MIS-C/A), and longCOVID.

An important breakthrough to unravel the pathogenesis of COVID-19 came from our two Science papers that were recognized by Nature among the top 10 discoveries of 2020. We found that about 4% of patients with critical COVID-19 pneumonia had inborn errors of immunity (IEI) that impair TLR3- and IRF7-dependent type I interferon (IFN) immunity and at least 10% of the patients carried pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs.

These findings pave the way for further studies of COVID-19 pneumonia and other SARS-CoV-2 infection phenotypes and form the basis of the present research proposal, UNDINE, which follows a ""bed side to bench"" and ""bench to bed side"" approach, with the following objectivies i) to decipher the genetic and immunological basis of the various SARS-CoV-2 disease manifestations, to identify individuals at increased risk of critical COVID-19, post-infectious immunological complications, and vaccine failure iii) to develop ready-to-use diagnostic tests for large-scale detection of auto-Abs to type I IFNs and propose novel preventive and therapeutic approaches, based on the pathogenesis of SARS-CoV-2 infection for translation into personalised medicine.

To achieve these goals, our project will coordinate a European multidisciplinary and translational research effort relying on a strong and synergistic combination of assets, including unique cohorts from 11 EU countries and state-of-the art human genetic, immunological and virological expertises and technologies.""

Topics

Who is involved

OrganisationCityCountryRole
Aarhus UniversitetAarhus CDenmarkCoordinator
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Centre Hospitalier Universitaire VaudoisLausanneSwitzerlandAssociatedpartner
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandAssociatedpartner
Deutsches Primatenzentrum GmbHGottingenGermanyParticipant
Aarhus UniversitetshospitalAarhusDenmarkParticipant
Tartu UlikoolTartuEstoniaParticipant
Idryma Iatroviologikon Ereunon Akademias AthinonAthinaGreeceParticipant
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainThird party
Fundacio Institut D'investigacio Biomedica De BellvitgeL'Hospitalet De LlobregatSpainThird party
Institut Catala De La SalutBarcelonaSpainParticipant
Institut De Investigacio En Ciencies De La Salut Germans Trias I PujolBadalona BarcelonaSpainThird party
Servicio Madrileno De SaludMadridSpainParticipant
Biomerieux SAMarcy-l'EtoileFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Institut PasteurParisFranceParticipant
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Ospedale San Raffaele SRLMilanoItalyParticipant
Universita Degli Studi Di Roma Tor VergataRomaItalyParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Karolinska InstitutetStockholmSwedenParticipant
Imperial College of Science Technology and MedicineLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI